Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy
A New Era in Schizophrenia Care: National Council for Mental Wellbeing and Bristol Myers Squibb Collaborate to Advance Evidence-Based Care Models
Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos Data at American College of Cardiology Annual Scientific Session & Expo 2026
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo®
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
U.S. FDA Approves Bristol Myers Squibb's Sotyktu® for the Treatment of Adults with Active Psoriatic Arthritis
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha -Thalassemia
Syntholene Energy Corp. Announces Engagement of DS Market Solutions Inc. for Liquidity Services and Emerging Markets Consulting for Communications and Marketing Services
Skyharbour Announces Drilling Underway and Renewed Permit at the High-Grade Moore Lake Uranium Project, Saskatchewan
Gold Runner Exploration Announces Closing of Upsized Institutionally Supported Non-Brokered Private Placement Financing of Flow-Through Units and Charity Flow Through Units for $3.1 Million
